Neurotop Retard (Carbamazepine)

Carbamazepine, the active ingredient in Neurotop Retard, is an Anticonvulsant presented as a tablet for Oral use. It is employed to control partial (focal) seizures, relieve neuropathic facial pain in trigeminal neuralgia, and stabilize mood during manic episodes of bipolar disorder, primarily in adult patients.

GNH USA supplies Neurotop Retard as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics across global markets, ensuring quality and regulatory compliance.

Neurotop Retard (carbamazepine) is indicated for several neurological and psychiatric conditions. - Epilepsy (partial seizures): reduces seizure frequency and severity. - Trigeminal neuralgia: relieves neuropathic facial pain. - Bipolar disorder (manic episodes): stabilizes mood and diminishes manic symptoms.

Carbamazepine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Drowsiness or fatigue - Nausea or vomiting - Blurred vision - Constipation - Skin rash

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Aplastic anemia or agranulocytosis - Severe hepatic dysfunction - Hyponatremia (low blood sodium) - Severe skin reactions (e.g., drug rash with eosinophilia and systemic symptoms) - Blood dyscrasias such as leukopenia

Before initiating therapy, clinicians should assess patient history and monitor relevant parameters. - Blood count monitoring: perform baseline and periodic complete blood counts. - Liver function monitoring: assess hepatic enzymes before and during treatment. - Discontinuation: avoid abrupt cessation to prevent seizure exacerbation. - Renal impairment: adjust dose cautiously in patients with reduced renal function. - Pregnancy and lactation: evaluate risk‑benefit ratio; use only if clearly needed. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Carbamazepine interacts with several medicines; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension or serotonin syndrome. - Erythromycin and other macrolide antibiotics: increase carbamazepine plasma levels, raising toxicity risk. - Azole antifungals (e.g., ketoconazole): inhibit metabolism, leading to elevated drug concentrations.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase carbamazepine levels and cause hepatic toxicity. - Oral contraceptives: carbamazepine can reduce hormonal efficacy, risking unintended pregnancy. - NSAIDs: may enhance carbamazepine‑induced hematologic effects; monitor blood counts.